$JNJ

Johnson & Johnson (JNJ) stock is at $275.66, up 59.3% over the past year. Recent FDA approvals for Ottava robotic surgery and IMAAVY drug, along with revenue growth, have driven upgrades. Analysts' price targets range from $249.03 (InvestingPro) to $320 (UBS), with a consensus of $277. JNJ's valuation metrics include P/E (31.6x LTM, 24.9x forward), EV/EBITDA (19.9x), and a 1.9% dividend yield. Bullish factors include oncology growth, robotics, and a strong balance sheet, while bears point to val

Schmid Timothy (EVP, WW Chair, MedTech) sold 33,597 shares of JOHNSON & JOHNSON (JNJ) at $274.74 ($9.23M total) across 2 trades on 2026-09-02.

RBC Capital's Larry Biegelsen maintained an Overweight rating on Johnson & Johnson (JNJ) and raised the price target to $272 from $263, reflecting confidence in the company's valuation and future earnings.

J&J shares rose 1% to $277.955. AbbVie's experimental myeloma drug showed 74% response rate, 60% risk reduction. J&J's Carvykti drove 6.8% operational growth in Q2. Reuters notes AbbVie's drug complements, not replaces, J&J's treatment. J&J's stock is 44.08% above GF Value estimate.

Broadcom (AVGO) reported Q3 non-GAAP EPS of $3.32, revenue up 85.5% Y/Y to $29.59B, and guided Q4 revenue at $34.8B. Uber (UBER) announced a 10% workforce cut, stock up 1.61% to $76.45. J&J (JNJ) traded at $281.07 before closing at $275.21.

Timothy Schmid plans to sell 33,597 shares of Johnson & Johnson (JNJ) common stock, valued at $9.23 million, under Rule 144. The sale is scheduled for September 2, 2026, and the shares will be issued from a stock option exercise with the company, settled in cash.

Johnson & Johnson shares rose 2.7% to $278.63 after FDA approved its drug Imaavy for a rare disease, and UBS raised its price target to $320. The stock has gained 50% in the past year, nearing record highs. The company also raised its 2026 sales target above $100 billion.

A federal judge dismissed Johnson & Johnson's libel lawsuit against three researchers who linked talc to mesothelioma, ruling the company couldn't prove malice. The case involved discrepancies in studies about asbestos exposure from talc products. J&J has faced multiple lawsuits over its talc-based baby powder and has sued researchers, but courts have dismissed these cases.

Taiwan's FDA issued a red alert over a heart pump device after the U.S. FDA warned of a defect in Abiomed Inc.'s Automated Impella Controllers, linked to 3 deaths and 37 injuries. The device, used in 19 Taiwanese hospitals, is being recalled for a cartridge recognition issue. Johnson & Johnson MedTech, the local license holder, must notify providers and implement fixes.

U.S. President Trump has secured drug-pricing deals with over 20 pharmaceutical companies, including Pfizer, Johnson & Johnson, and Novo Nordisk, to reduce prescription costs. Agreements involve 'most-favoured-nation' pricing, sales through TrumpRx.gov, and U.S. investment pledges in exchange for tariff relief. Companies like Pfizer and Novo Nordisk have committed to significant price reductions on specific drugs.